000			04026nam a22003855i 4500
001			289309
003			MX-SnUAN
005			20160429154705.0
007			cr nn 008mamaa
008			150903s2009 xxu| o |||| 0|eng d
020			_a9781607611783 _99781607611783
024	7		_a10.1007/9781607611783 _2doi
035			_avtls000343318
039		9	_a201509030846 _bVLOAD _c201405050255 _dVLOAD _y201402061153 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aSiddik, Zahid H. _eeditor. _9305472
245	1	0	_aCheckpoint Controls and Targets in Cancer Therapy / _cedited by Zahid H. Siddik.
250			_a1.
264		1	_aTotowa, NJ : _bHumana Press, _c2009.
300			_axiv, 274 páginas 60 ilustraciones, 30 ilustraciones en color. _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCancer Drug Discovery and Development
500			_aSpringer eBooks
505	0		_aCircuitry of Checkpoint Response -- Evasion of G1 Checkpoints in Cancer -- Distinct Pathways Involved in S-Phase Checkpoint Control -- Mechanisms of G2 Phase Arrest in DNA Damage-Induced Checkpoint Response -- Centrosomes in Checkpoint Responses -- Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control -- Checkpoint Response and the Aetiology of Cancer -- Chromatin Modifications and Orchestration of Checkpoint Response in Cancer -- DNA Damage Response and the Balance Between Cell Survival and Cell Death -- Dysfunction of the RB Retinoblastoma Gene in Cancer -- G1 Phase Cyclins in Cancer Development and Progression -- The BRCA1/2 Pathway Prevents Some Leukemias and Lymphomas in Addition to Breast/Ovarian Cancers: Malignancies that Overcome Checkpoint Controls -- Targeting Checkpoint Response in Cancer Therapy -- Regulation of p53 Activity and Associated Checkpoint Controls -- The Importance of p53 Signaling in the Response of Cells to Checkpoint Inhibitors -- Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy -- p27Kip1 as a Biomarker and Target for Treatment of Cancer -- Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors -- Chk1 and Chk2 as Checkpoint Targets -- Targeting Cdc25 Phosphatases in Cancer Therapy.
520			_aThere is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are closely associated with cancers that are highly resistant to therapeutic interventions. Checkpoint Controls and Targets in Cancer provides present-day mechanistic understandings of how multiple sets of proteins orchestrate cell cycle progression, discusses critical checkpoint controls that are evaded for cancer development, focuses on checkpoint pathways associated with antitumor effects, and identifies specific checkpoint regulators for targeting with small molecules in the clinical management of cancer. These aspects of cell cycle checkpoints are articulated critically by renowned experts from both academia and industry, and new concepts are forwarded that challenge existing dogmas. Collectively, Checkpoint Controls and Targets in Cancer provides a unique collection of insightful contributions, which are timely and offer significant interest and appeal to basic, translational and clinical scientists.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781607611776
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-60761-178-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289309 _d289309